Safety and tolerance of methylnaltrexone in healthy humans: A randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study

Journal of Clinical Pharmacology

Volumn 37, Issue 1, 1997, Pages 25-30

  Foss, Joseph F ^a   O'Connor, Michael F ^a   Yuan, Chun Su ^a   Murphy, Michael ^a   Moss, Jonathan ^a   Roizen, Michael F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; HISTAMINE; OPIATE ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; HISTAMINE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PAIN; RANDOMIZED CONTROLLED TRIAL;

EID: 0030937053     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009703700105     Document Type: Article

References (18)

1. Valentino RJ, Katz JL, Medzihradsky F, Woods JH: Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 1983;32:2887-2896.
2. Brown DR, Goldberg LI: The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24:181-191.
3. Brown DR, Robertson MJ, Goldberg LI: Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives. Neuropharmacology 1983;22:317-321.
4. Gmerek DE, Cowan A, Woods JH: Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharm Exp Ther 1986;236:8-13.
5. Manara L, Bianchetti A: The central and peripheral influences of opioids on gastrointestinal propulsion. Ann Rev Pharmacol Toxicol 1985;25:249-273.
6. Foss JF, Orelind E, Goldberg LI: Effects of methylnaltrexone on morphine-induced cough suppression in guinea-pigs. Life Sci (in press).
7. Foss JF, Bass AS, Goldberg LI: Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharm 1993;33:747-751.
8. Kim C, Cheng R, Corrigal WA: Measurement of naltrexone in rat brain regions and serum by high performance liquid chromatography with electrochemical detection. Chromatographia 1988;25:91-94.
9. Kim C, Cheng R, Corrigal WA: Assay for methylnaltrexone in rat brain regions and serum by high-performance liquid chromatography with coulometric electrochemical detection. Chromatographia 1989;28:359-363.
10. McBride P, Bradley D, Kaliner MJ: Evaluation of a radioimmunoassay for histamine measurement in biological fluids. J Allergy Clin Immunol 1988;82:638-646.
11. Moss J, Rosow CE, Savarese JJ, Philibin DM, Kniffen KJ: Role of histamine in the hypotensive action of d-tubocurarine in man. Anesthesiology 1981;55:19-25.
12. Trenchard E, Silverstone, T: Naloxone reduces the food intake of normal volunteers. Appetite 1983;4:43-50.
13. Lien CA, Belmont MR, Abalos A, Larissa E, Quessy S, Abou-Donia MM, Savarese JJ: The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/ opioid/barbiturate anesthesia. Anesthesiology 1985;82:1131-1138.
14. Savarese JJ, Ali HH, Basta SJ, Scott RP, Embree PB, Wastila WB, et al: The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. Anesthesiology 1989;70:386-394.
15. Walsh TD: Oral morphine in chronic cancer pain. Pain 1984;18:1-11.
16. Glare P, Lickiss JN: Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage 1992;7:369-371.
17. Portenoy RK: Constipation in the cancer patient: Causes and management. Med Clin North Am 1987;71:303-311.
18. Fifield MY: Relieving constipation and pain in the terminally ill. Am J Nurs 1991;91(7):18-19.